C Peptide Fails to Improve the Utility of the DiaRem Algorithm in Predicting Remission of Type II Diabetes After Bariatric Surgery

Abstract

We evaluated the utility of C peptide as an addition to the DiaRem score for predicting type 2 diabetes (T2D) remission 1 year after bariatric surgery in 175 patients. DiaRem score was significantly correlated with C peptide (r = − .43; p < .001). Both DiaRem and C peptide were significant predictors of remission of T2D (OR (95% CI) = .81 (.75–.86); p < 0001 and OR (95% CI) = 1.35 (1.15–1.60); p < .001, respectively). ROC analysis indicated that DiaRem was a significantly stronger predictor than C peptide (p < .001). Hierarchical regression indicated that C peptide failed to significantly improve the prediction of diabetes remission after accounting for DiaRem (OR (95% CI) = 1.079 (.87–1.26); p = .406). This study does not support the inclusion of C peptide in the DiaRem algorithm.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol. Jan 2014;2(1):38–45.

    Article  Google Scholar 

  2. 2.

    Aminian A, Brethauer SA, Kashyap SR, et al. DiaRem score: external validation. Lancet Diabetes Endocrinol. 2014;2:12–3.

    Article  Google Scholar 

  3. 3.

    Craig Wood G, Horwitz D, Still CD, et al. Performance of the DiaRem score for predicting diabetes remission in two health systems following bariatric surgery procedures in Hispanic and non-Hispanic white patients. Obes Surg. 2018;28:61–8.

    CAS  Article  Google Scholar 

  4. 4.

    Adams TD, Arterburn DE, Nathan DM, et al. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care. 2016;39:912–23.

    CAS  Article  Google Scholar 

  5. 5.

    Park JY, Kim YJ. Prediction of diabetes remission in morbidly obese patients after Roux-en-Y gastric bypass. Obes Surg. 2016;26:749–56.

    Article  Google Scholar 

  6. 6.

    Kao PC, Taylor RL, Heser DW. C-peptide immunochemiluminometric assay developed from two seemingly identical polyclonal antisera. Ann Clin Lab Sci. 1992;22:307–16.

    CAS  PubMed  Google Scholar 

  7. 7.

    Lee WJ, Chong K, Chen SC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26:2418–24.

    Article  Google Scholar 

  8. 8.

    Pucci A, Tymoszuk U, Cheung WH, et al. Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabet Med. 2018;35:360–7.

    CAS  Article  Google Scholar 

  9. 9.

    Aron-Wisnewsky J, Sokolovska N, Yuejun L, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2020;60:892–1902.

    Google Scholar 

  10. 10.

    Kam H, Tu Y, Pan J, et al. Comparison of four risk prediction models for diabetes remission after Roux-en-Y gastric bypass surgery in obese Chinese patients with type 2 diabetes mellitus. Obes Surg. 2020;30(6):2147–57.

    Article  Google Scholar 

  11. 11.

    Khorgami Z, Zhang C, Messiah SE, et al. Predictors of postoperative aftercare attrition among gastric bypass patients. Bariatr Surg Pract P. 2015;10(2):79–83.

    Google Scholar 

  12. 12.

    Kedestig J, Stenberg E. Loss to follow-up after laparoscopic gastric bypass surgery – a post hoc analysis of a randomized clinical trial. SOARD. 2019;15:880–6.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pavlos K. Papasavas.

Ethics declarations

Conflict of Interest

RLS: no conflict of interest. TM: no conflict of interest. MO: no conflict of interest. IS: no conflict of interest. AS: no conflict of interest. DU: no conflict of interest. DT served as a consultant for Olympus, Medtronic, Conmed and Intuitive. PKP: no conflict of interest.

Statement of Informed Consent

Informed consent does not apply. This study was approved by the Institutional Review Board with a waiver of informed consent.

Ethical Approval

This study was approved by the Institutional Review Board. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Seip, R.L., McLaughlin, T., O’Brien, M. et al. C Peptide Fails to Improve the Utility of the DiaRem Algorithm in Predicting Remission of Type II Diabetes After Bariatric Surgery. OBES SURG (2021). https://doi.org/10.1007/s11695-021-05227-x

Download citation

Keywords

  • DiaRem
  • Sleeve gastrectomy
  • Gastric bypass
  • Gastric banding
  • Diabetes